Rocuronium: high risk for anaphylaxis?
Patients suspected of anaphylaxis during anaesthesia have been referred to the senior author's clinic since 1974 for investigation. Since release of rocuronium on to the worldwide market, concern has been expressed about its propensity to cause anaphylaxis. We identified 24 patients who met clinical and laboratory (intradermal, mast cell tryptase and morphine radioimmunoassay) criteria for anaphylaxis to rocuronium. The incidence of rocuronium allergy in New South Wales, Australia has risen in parallel with sales, while there has been an associated fall in reactions to other neuromuscular blocking drugs. Data from intradermal testing suggested that rocuronium is intermediate in its propensity to cause allergy in known relaxant reactors compared with low-risk agents (e.g. pancuronium, vecuronium) and higher-risk agents (e.g. alcuronium, succinylcholine).
Rose
M
M
Royal North Shore Hospital of Sydney, St Leonards, NSW, Australia.
Fisher
M
M
D000707:Anaphylaxis / Q000139:chemically induced* / Q000175:diagnosis; D000732:Androstanols / Q000009:adverse effects* / Q000276:immunology; D003429:Cross Reactions; D005260:Female; D006801:Humans; D007428:Intradermal Tests / Q000379:methods; D008297:Male; D009466:Neuromuscular Blocking Agents / Q000009:adverse effects / Q000276:immunology; D003473:Neuromuscular Nondepolarizing Agents / Q000009:adverse effects* / Q000276:immunology; D018570:Risk Assessment; D000077123:Rocuronium
D000732:Androstanols; D009466:Neuromuscular Blocking Agents; D003473:Neuromuscular Nondepolarizing Agents; D000077123:Rocuronium